Imugene Ltd (ASX:IMU, OTC:IUGNF) will present its HER-Vaxx and CF33 technologies at the ASCO Gastrointestinal Cancers Symposium in San Francisco from January 19-21.
The 20th annual international event will highlight the latest developments and breakthroughs in the field of gastrointestinal oncology and will be attended by more than 4,000 clinical researchers, academics, oncologists and medical practitioners from around the world.
The clinical stage immuno-oncology company will feature in the following sessions:
- Oral Abstract Session
- HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma - Overall survival analysis.
- Trials in Progress Poster Session
- nextHERIZON: A Phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
- Poster Session
- Development of a novel chimeric oncolytic viral platform, CF33 and its derivatives, for peritoneal-directed CF33-OV treatment of gastric cancer peritoneal carcinomatosis.
- Ex vivo oncolytic and immune activity of CF33-hNIS-antiPDL1 against fresh peritoneal cells from patients with gastric cancer with and without peritoneal metastases.
Developing effective cancer treatments
Imugene’s unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR-Ts for solid tumours.
Supported by a team of international cancer experts with extensive experience in developing and marketing new cancer therapies, IMU wants to improve the treatment of cancer with clinical evidence and peer-reviewed research.